1A33.0) - Cystoisosporiasis of the Small Intestine: Complete Coding Guide

Q: How is the diagnosis of cystoisosporiasis of the small intestine made?

The diagnosis is established by the identification of *Cystoisospora belli* oocysts in stool samples or intestinal tissue. The parasitological examination of stool should use concentration techniques (such as Ritchie or Faust) followed by modified Ziehl-Neelsen or auramine-rhodamine staining, which highlight the characteristic ovoid oocysts, measuring 20-30 micrometers. Since oocyst shedding may be intermittent, it is recommended to collect at least three samples on alternate days. Alternatively

1. Introduction

Small intestine cystoisosporiasis is a parasitic infection caused by the protozoan Cystoisospora belli (formerly known as Isospora belli), which specifically affects the small intestine, causing chronic watery diarrhea and intestinal malabsorption. This condition represents a significant clinical challenge, particularly in immunocompromised patients, where it can progress to severe and debilitating presentations.

The clinical importance of this parasitosis lies mainly in its association with patients with HIV/AIDS, organ transplant recipients, and individuals undergoing immunosuppressive therapies. In immunocompetent patients, the disease tends to be self-limited, but in hosts with compromised immunity, it can become chronic, causing severe malnutrition, significant weight loss, and progressive deterioration of general health status.

From an epidemiological perspective, cystoisosporiasis presents worldwide distribution, being more prevalent in tropical and subtropical regions with inadequate sanitary conditions. Transmission occurs through the fecal-oral route, via ingestion of mature oocysts present in contaminated water or food. The impact on public health is considerable, especially in areas with high HIV prevalence and deficient sanitary infrastructure.

Correct coding using ICD-11 is critical for multiple aspects of medical care: it enables precise epidemiological tracking of the disease, facilitates prevalence and incidence studies, guides public health policies, ensures adequate reimbursement for services provided, and enables analysis of clinical outcomes. The specificity of code 1A33.0, which identifies small intestine involvement, is fundamental to differentiate this presentation from other forms of cystoisosporiasis, allowing for more precise treatment and prognosis.

2. Correct ICD-11 Code

Code: 1A33.0

Description: Cystoisosporiasis of the small intestine

Parent category: 1A33 - Cystoisosporiasis

This specific code identifies infection by Cystoisospora belli when there is confirmation of small intestine involvement. The ICD-11 classification maintains a hierarchical structure where 1A33 represents all forms of cystoisosporiasis, while 1A33.0 specifies the anatomical location in the small intestine, which is the most common and clinically relevant presentation of this parasitosis.

Precise coding requires diagnostic confirmation through laboratory methods, preferably by identification of oocysts in feces or in small intestine biopsies. The location in the small intestine is generally inferred by the characteristic clinical presentation of watery diarrhea with malabsorption, and can be confirmed by upper gastrointestinal endoscopy with duodenal or jejunal biopsies.

It is important to emphasize that this code should be used when there is clear evidence of small intestine involvement, whether by typical clinical manifestations, endoscopic findings, or histopathological confirmation. Adequate documentation of anatomical location is essential to justify the use of this specific code instead of the generic code of the parent category.

3. When to Use This Code

Scenario 1: HIV-positive patient with chronic diarrhea and identified oocysts

A patient with confirmed HIV/AIDS diagnosis, presenting with CD4 count below 200 cells/mm³, develops profuse watery diarrhea for more than four weeks. Parasitological stool examination with concentration techniques and modified Ziehl-Neelsen staining reveals oocysts of Cystoisospora belli. The patient presents signs of malabsorption, including significant weight loss and steatorrhea. In this case, code 1A33.0 is appropriate, as there is parasitological confirmation and the clinical presentation is consistent with small intestine involvement.

Scenario 2: Endoscopy with biopsy confirming duodenal cystoisosporiasis

A renal transplant patient on immunosuppressive therapy develops persistent diarrhea. Upper gastrointestinal endoscopy reveals edematous and friable duodenal mucosa. Duodenal biopsies demonstrate the presence of evolutionary forms of Cystoisospora belli in the intestinal epithelium, with characteristic villous alterations. This is a clear case for using code 1A33.0, as there is histopathological confirmation of small intestine involvement.

Scenario 3: Chronic diarrhea with documented malabsorption

An immunocompromised patient presents with watery diarrhea for six weeks, with intestinal function tests showing malabsorption of fats and D-xylose. Serial stool examination identifies oocysts of Cystoisospora belli. Even without endoscopy, the combination of documented malabsorption and parasite identification justifies code 1A33.0, as malabsorption indicates small intestine involvement.

Scenario 4: Recurrence of intestinal cystoisosporiasis

A patient previously treated for small intestine cystoisosporiasis returns with symptom recurrence after discontinuation of suppressive therapy. New parasitological examination confirms the presence of oocysts. Code 1A33.0 remains appropriate for this episode of recurrence, with clear documentation that this is a recurrence.

Scenario 5: Molecular diagnosis with typical symptoms

A patient with immunodeficiency syndrome presents with chronic watery diarrhea. Molecular techniques (PCR) applied to fecal samples identify Cystoisospora belli DNA. The clinical presentation with watery diarrhea, abdominal cramping, and weight loss strongly suggests small intestine involvement. Code 1A33.0 is appropriate when there is molecular confirmation and compatible symptomatology.

Scenario 6: Coinfection identified in HIV context

A patient with advanced AIDS presents with multiple opportunistic infections. During investigation of chronic diarrhea, Cystoisospora belli is identified in stool, along with other pathogens. Code 1A33.0 should be used for small intestine cystoisosporiasis, together with additional codes for the other identified infections.

4. When NOT to Use This Code

Code 1A33.0 should not be used when cystoisosporiasis primarily affects the colon, in which case the appropriate code would be 1A33.1 (Cystoisosporiasis of colon). Differentiation is usually made by colonoscopy with biopsies or when the clinical presentation strongly suggests colitis, with the presence of mucus and blood in the stool.

Do not use this code for other intestinal parasitoses that may cause similar symptoms, such as cryptosporidiosis (code 1A36), microsporidiosis (codes 1A3A), giardiasis (code 1A35), or cyclosporiasis (code 1A34). Although these conditions may present with similar clinical presentations, they are caused by different etiologic agents and require specific coding.

Avoid using 1A33.0 when there is only clinical suspicion without laboratory confirmation. In cases of chronic diarrhea under investigation, use appropriate symptom codes until parasitological diagnosis is established. Laboratory confirmation is essential to justify the use of this specific code.

The code should also not be applied to asymptomatic carriers of Cystoisospora belli, who may occasionally be identified on routine examinations without clinical manifestations. In these cases, codes related to asymptomatic carriers or incidental laboratory findings would be more appropriate.

Do not use this code when diarrhea is attributable to other causes in patients who incidentally present with oocysts in the stool without evidence of active disease. The presence of the parasite must be causally related to the symptoms presented.

5. Coding Step by Step

Step 1: Assess diagnostic criteria

The diagnosis of small intestine cystoisosporiasis requires laboratory confirmation through identification of Cystoisospora belli oocysts in clinical samples. The most common method is parasitological stool examination using concentration techniques (Ritchie, Faust) followed by modified Ziehl-Neelsen or auramine-rhodamine staining, which highlight the characteristic ovoid oocysts.

Alternatively, diagnosis can be established by intestinal biopsy obtained during upper gastrointestinal endoscopy, where histopathological examination reveals evolutionary forms of the parasite in the small intestine epithelium, frequently accompanied by inflammatory changes and villous atrophy. Molecular methods such as PCR can also confirm the diagnosis, especially when microscopic examinations are negative despite strong clinical suspicion.

Typical clinical presentation includes chronic watery diarrhea (persisting for more than two weeks), abdominal cramps, nausea, anorexia, low-grade fever, and weight loss. In immunocompromised patients, symptoms tend to be more intense and prolonged. Signs of intestinal malabsorption, such as steatorrhea and nutritional deficiencies, reinforce the diagnosis of small intestine involvement.

Step 2: Verify specifiers

Although code 1A33.0 does not have formal subdivisions in ICD-11, it is important to document relevant clinical characteristics: symptom duration (acute versus chronic), severity (mild, moderate, severe), patient immunological status (immunocompetent versus immunocompromised), and treatment response.

Severity can be classified based on evacuation frequency, degree of dehydration, nutritional impact, and need for hospitalization. Patients with more than ten daily evacuations, severe dehydration, or significant nutritional compromise present severe disease requiring appropriate documentation.

The clinical context, especially the presence of immunosuppression, should be clearly recorded, as it influences prognosis and the need for prolonged suppressive therapy. Use additional codes to document HIV/AIDS, organ transplantation, or other immunosuppressive conditions.

Step 3: Differentiate from other codes

The main differentiation within category 1A33 is with code 1A33.1 - Cystoisosporiasis of the colon. The distinction is based on the predominant anatomical location of infection. Small intestine involvement (1A33.0) typically manifests with profuse watery diarrhea, malabsorption, and weight loss, whereas colonic involvement (1A33.1) may present with mucoid diarrhea, blood, and tenesmus.

When there is simultaneous involvement of small intestine and colon, the code should reflect the predominant or most clinically significant location. If both segments are equally affected, use the parent category code (1A33) or both specific codes when the system allows multiple coding.

Also differentiate from other causes of chronic diarrhea in immunocompromised patients: cryptosporidiosis (smaller, spherical oocysts), microsporidiosis (very small spores, requiring special techniques), cyclosporiasis (larger, autofluorescent oocysts), and giardiasis (characteristic trophozoites and cysts).

Step 4: Required documentation

Adequate documentation should include: date of symptom onset, detailed description of diarrhea (frequency, consistency, presence of blood or mucus), associated symptoms (fever, abdominal pain, nausea), patient immunological status (CD4 count in HIV-positive patients, immunosuppressive medications), results of confirmatory laboratory tests (date, method used, description of oocysts).

Also record endoscopy findings when performed (mucosal appearance, biopsy locations), histopathological results, nutritional assessment (weight, body mass index, serum albumin), signs of dehydration, and instituted treatment. This complete documentation justifies specific coding and allows for proper audit.

Maintain records of serial stool examinations, as oocyst shedding may be intermittent, and diagnostic confirmation may require multiple samples. Also document response to specific treatment, as clinical improvement with anti-Cystoisospora therapy reinforces the diagnosis.

6. Complete Practical Example

Clinical Case

A 38-year-old patient with HIV for five years presents to the infectious disease service with a complaint of watery diarrhea for six weeks. He reports liquid bowel movements, without visible blood or mucus, with a frequency of eight to twelve times per day, accompanied by diffuse abdominal cramping, occasional nausea, and low-grade intermittent fever. He reports a weight loss of approximately eight kilograms during this period.

The patient had discontinued antiretroviral therapy four months ago due to difficulties accessing health services. On physical examination, he appears emaciated and dehydrated, with reduced skin turgor and dry mucous membranes. Abdomen slightly distended, tympanic, with increased bowel sounds, without palpable masses or organomegaly.

Laboratory tests reveal CD4 count of 85 cells/mm³, elevated HIV viral load, mild anemia (hemoglobin 10.2 g/dL), hypoalbuminemia (2.8 g/dL), and electrolytes showing mild hyponatremia and hypokalemia. Parasitological stool examination was requested using concentration technique and modified Ziehl-Neelsen staining.

Three stool samples collected on alternate days revealed the presence of ovoid oocysts, measuring approximately 20-30 micrometers, stained red by the modified Ziehl-Neelsen technique, characteristic of Cystoisospora belli. No other parasites or bacterial pathogens were identified in stool cultures.

Step-by-Step Coding

Criteria analysis:

Laboratory confirmation: Cystoisospora belli oocysts identified in three stool samples
Compatible clinical presentation: Chronic watery diarrhea, weight loss, signs of malabsorption
Anatomical location: Symptoms indicate small intestine involvement (profuse watery diarrhea, malabsorption evidenced by hypoalbuminemia and weight loss)
Clinical context: Immunocompromised patient (HIV with low CD4)

Code selected: 1A33.0 - Cystoisosporiasis of the small intestine

Complete justification: Code 1A33.0 is appropriate because there is definitive parasitological confirmation through microscopic identification of Cystoisospora belli oocysts in multiple stool samples. The clinical presentation with profuse watery diarrhea, significant weight loss, and hypoalbuminemia clearly indicates small intestine involvement, which is the primary site of infection by this parasite. There is no clinical or endoscopic evidence of predominant colonic involvement, which would preclude the use of code 1A33.1.

Applicable complementary codes:

1C62.Z - Disease caused by human immunodeficiency virus without mention of another condition (to document HIV as the underlying condition)
5B5Z - Protein-calorie malnutrition, unspecified (to document nutritional compromise)
[ME05.0](/en/code/ME05.0) - Dehydration (to document the complication present)

This case illustrates the importance of laboratory confirmation, detailed clinical evaluation, and adequate documentation of the immunological context for precise coding of cystoisosporiasis of the small intestine.

7. Related Codes and Differentiation

Within the Same Category

1A33.1: Cystoisosporiasis of the colon

The main difference between 1A33.0 and 1A33.1 lies in the predominant anatomical location of the infection. Cystoisosporiasis of the small intestine (1A33.0) typically manifests with voluminous watery diarrhea, nutrient and fat malabsorption, marked weight loss, and rarely presents with blood or mucus in the stool. Diagnosis can be confirmed by upper gastrointestinal endoscopy with duodenal or jejunal biopsies.

In contrast, cystoisosporiasis of the colon (1A33.1) may present with features of colitis, including diarrhea with mucus, occasionally blood, tenesmus, and fecal urgency. Diagnosis of this form is generally established by colonoscopy with colonic biopsies showing the parasite.

In clinical practice, small intestine involvement is much more common, representing the typical presentation of cystoisosporiasis. Isolated colonic involvement is rare. When there is doubt about the location, the code 1A33 (parent category, without specification of location) can be used until additional investigation clarifies the anatomical extent of the infection.

Differential Diagnoses

Cryptosporidiosis (1A36): Caused by Cryptosporidium spp., presents very similar symptoms in immunocompromised patients. Differentiation is made by microscopic identification of oocysts, which in cryptosporidiosis are smaller (4-6 micrometers), spherical, and in greater number than those of Cystoisospora.

Cyclosporiasis (1A34): Caused by Cyclospora cayetanensis, also presents with chronic watery diarrhea. The oocysts are larger (8-10 micrometers), spherical, and exhibit autofluorescence under ultraviolet light, a characteristic useful for differentiation.

Intestinal microsporidiosis (1A3A): Caused by various microsporidia, requires special staining techniques (Gram-chromotrope, calcofluor white) or electron microscopy for identification of very small spores (1-2 micrometers).

Giardiasis (1A35): Although it causes diarrhea and malabsorption, it is easily differentiated by the identification of trophozoites and cysts of Giardia lamblia, morphologically distinct from the oocysts of Cystoisospora.

8. Differences with ICD-10

In ICD-10, cystoisosporiasis was coded as A07.3 - Isosporiasis, reflecting the former nomenclature of the parasite (Isospora belli). This code did not distinguish between different anatomical locations of infection, treating all forms of cystoisosporiasis under a single code.

The main change in ICD-11 is the update of nomenclature to reflect the taxonomic reclassification of the parasite as Cystoisospora belli and the introduction of anatomical specificity through codes 1A33.0 (small intestine) and 1A33.1 (colon). This subdivision allows more precise documentation of infection location and better epidemiological tracking.

The practical impact of these changes includes greater specificity in coding, allowing more detailed analyses of disease patterns, preferential anatomical location, and treatment response. For professionals accustomed to ICD-10, it is important to recognize that the former code A07.3 now corresponds mainly to 1A33.0, since small intestine involvement is the classic presentation.

The transition to ICD-11 requires updating electronic health record systems, training of coders, and review of documentation protocols to ensure that anatomical location is adequately recorded. This additional specificity, although requiring initial adaptation, offers significant benefits for clinical research and public health management.

9. Frequently Asked Questions

How is the diagnosis of cystoisosporiasis of the small intestine made?

The diagnosis is established by the identification of Cystoisospora belli oocysts in stool samples or intestinal tissue. The parasitological examination of stool should use concentration techniques (such as Ritchie or Faust) followed by modified Ziehl-Neelsen or auramine-rhodamine staining, which highlight the characteristic ovoid oocysts, measuring 20-30 micrometers. Since oocyst shedding may be intermittent, it is recommended to collect at least three samples on alternate days. Alternatively, duodenal biopsies obtained by upper gastrointestinal endoscopy may reveal evolutionary forms of the parasite in the intestinal epithelium. Molecular methods such as PCR offer high sensitivity and specificity, being useful when microscopy is negative despite strong clinical suspicion.

Is treatment available in public health systems?

The standard treatment for cystoisosporiasis uses sulfamethoxazole-trimethoprim, an antibiotic widely available in public health systems worldwide due to its low cost and multiple clinical indications. Typical therapy involves high doses for seven to ten days in immunocompetent patients, while immunocompromised patients may require prolonged treatment followed by maintenance suppressive therapy. Therapeutic alternatives include ciprofloxacin and pyrimethamine, also generally available. Treatment accessibility is usually not a significant problem, although the availability of specialized diagnostic tests may be limited in some regions, especially specific staining techniques or molecular methods.

How long does treatment last?

In immunocompetent patients, treatment with sulfamethoxazole-trimethoprim generally lasts seven to ten days, with complete resolution of symptoms in most cases. Immunocompromised patients, particularly those with HIV/AIDS and low CD4 counts, require more prolonged treatment, typically three to four weeks, followed by maintenance suppressive therapy with lower doses to prevent relapse. Suppressive therapy should be maintained until adequate immune reconstitution occurs, generally when CD4 count exceeds 200 cells/mm³ in a sustained manner for at least six months. Clinical response usually occurs within one week after starting treatment, with reduction in bowel movement frequency and improvement in general condition, although complete nutritional recovery may take several weeks.

Can this code be used in medical certificates?

Yes, code 1A33.0 can and should be used in medical certificates when appropriate, especially in contexts that require precise diagnostic documentation to justify absence from work or school. Cystoisosporiasis of the small intestine, particularly in immunocompromised patients, can cause significant debilitation that justifies temporary absence from activities. However, confidentiality considerations are important, especially when the disease is associated with HIV/AIDS. In some contexts, it may be preferable to use more generic codes or symptomatic descriptions to preserve patient privacy, depending on local regulations regarding medical confidentiality and patient rights. Always consider discussing with the patient the level of diagnostic specificity that will be included in documents that may be shared with employers or educational institutions.

Can cystoisosporiasis be transmitted from person to person?

Direct person-to-person transmission is considered uncommon, as oocysts shed in feces require a maturation period in the environment (sporulation) before becoming infectious, a process that takes 24-48 hours. The main transmission route is fecal-oral through water or food contaminated with sporulated oocysts. However, in situations of inadequate hygiene, secondary transmission may occur, especially in institutional settings or households with multiple immunocompromised individuals. Rigorous personal hygiene measures, including proper handwashing after using the bathroom and before handling food, are essential to prevent transmission. Caregivers of patients with cystoisosporiasis should be instructed on contact precautions and hygiene to minimize exposure risks.

Do treated patients develop permanent immunity?

Immunocompetent patients who recover from cystoisosporiasis generally develop protective immunity that reduces the risk of reinfection, although the duration and efficacy of this immunity are not completely understood. In contrast, immunocompromised patients often do not develop adequate immunity and are at high risk of relapse after discontinuation of treatment or suppressive therapy. Recurrences are common in HIV/AIDS patients who do not achieve adequate immune reconstitution, even after successful treatment of the acute episode. For this reason, prolonged suppressive therapy is recommended for patients with persistent severe immunosuppression. The best preventive strategy in HIV-positive patients is effective antiretroviral therapy to restore immune function.

How to differentiate cystoisosporiasis from other causes of chronic diarrhea?

Differentiation requires careful clinical evaluation and specific laboratory investigation. Clinically, cystoisosporiasis in immunocompromised patients presents with profuse, persistent watery diarrhea, significant weight loss, and signs of malabsorption. The epidemiological context (recent travel, exposure to contaminated water, immunological status) provides important clues. Laboratorially, specific identification of the parasite through stool examinations with appropriate techniques (modified Ziehl-Neelsen staining) is essential. Comprehensive investigation of chronic diarrhea in immunocompromised individuals should include screening for multiple pathogens (bacteria, parasites, viruses), stool cultures, tests for Clostridium difficile toxins, and when indicated, endoscopy with biopsies. The response to specific treatment with sulfamethoxazole-trimethoprim can also be diagnostic, with significant clinical improvement supporting the diagnosis of cystoisosporiasis.

What complications can occur if untreated?

In immunocompetent patients, untreated cystoisosporiasis generally resolves spontaneously within weeks, although it may cause significant discomfort and temporary weight loss. However, in immunocompromised patients, untreated infection can lead to serious complications including severe malnutrition with protein-calorie depletion, chronic dehydration with electrolyte disturbances, persistent malabsorption with vitamin deficiencies (especially fat-soluble vitamins A, D, E, K), anemia, progressive deterioration of general condition, and in extreme cases, can contribute to significant morbidity and mortality. Severe chronic diarrhea can also lead to perianal dermatological complications, impaired quality of life, and difficulty maintaining other drug therapies. Early and appropriate treatment is essential to prevent these complications, particularly in vulnerable populations.

Conclusion: Precise coding of cystoisosporiasis of the small intestine using ICD-11 code 1A33.0 requires adequate diagnostic confirmation, detailed clinical evaluation, and complete documentation of anatomical location. This guide provides the necessary tools for correct application of this code in various clinical scenarios, contributing to better epidemiological tracking, clinical management, and research of this important opportunistic parasitosis.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Cystoisosporiasis of the small intestine

Compartilhar